By Sabela Ojea
2seventy bio said it has reached an agreement with Novo Nordisk to sell its hemophilia A candidate and rights to its in vivo gene editing technology outside of oncology and gene editing for up to $40 million.
The biotechnology company on Wednesday said that the divestiture supports its exclusive focus on delivering Abecma in collaboration with Bristol Myers Squibb.
"Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with Hemophilia A will continue to progress," Chief Executive Chip Baird said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
06-26-24 1655ET